TY - JOUR
T1 - New strategies in pleural mesothelioma
T2 - BAP1 and NF2 as novel targets for therapeutic development and risk assessment
AU - Ladanyi, Marc
AU - Zauderer, Marjorie G.
AU - Krug, Lee M.
AU - Ito, Tatsuo
AU - McMillan, Robert
AU - Bott, Matthew
AU - Giancotti, Filippo
PY - 2012/9/1
Y1 - 2012/9/1
N2 - Malignant pleural mesothelioma (MPM) is a highly lethal cancer with limited therapeutic options. Recent work has focused on the frequent somatic inactivation of two tumor suppressor genes in MPM-NF2 (Neurofibromatosis type 2) and the recently identified BAP1 (BRCA associated protein 1). In addition, germline mutations in BAP1 have been identified that define a new familial cancer syndrome, which includes MPM,ocular melanoma, and other cancers. These recent advances may allow screening of high-risk individuals and the development of new therapies that target key pathways in MPM.
AB - Malignant pleural mesothelioma (MPM) is a highly lethal cancer with limited therapeutic options. Recent work has focused on the frequent somatic inactivation of two tumor suppressor genes in MPM-NF2 (Neurofibromatosis type 2) and the recently identified BAP1 (BRCA associated protein 1). In addition, germline mutations in BAP1 have been identified that define a new familial cancer syndrome, which includes MPM,ocular melanoma, and other cancers. These recent advances may allow screening of high-risk individuals and the development of new therapies that target key pathways in MPM.
UR - http://www.scopus.com/inward/record.url?scp=84865720268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865720268&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-11-2375
DO - 10.1158/1078-0432.CCR-11-2375
M3 - Article
C2 - 22825583
AN - SCOPUS:84865720268
SN - 1078-0432
VL - 18
SP - 4485
EP - 4490
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 17
ER -
